Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar BrentonKJ (21.09) Submitted: 11/12/2012 6:54:41 PM : Outperform Start Price: $0.00 CELG Score: 0

Good stock being hurt by the fiscal cliff. The hep C news wouldve sent it even higher otherwise.

Featured Broker Partners


Advertisement